Literature DB >> 17617419

A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay.

G G Kim1, V S Donnenberg, A D Donnenberg, W Gooding, T L Whiteside.   

Abstract

Natural killer (NK) cell-or T cell-mediated cytotoxicity traditionally is measured in 4-16 h (51)Cr-release assays (CRA). A new four-color flow cytometry-based cytotoxicity assay (FCC) was developed to simultaneously measure NK cell cytotoxicity and NK cell phenotype (CD3(-)CD16(+)CD56(+)). Target cells, K562 or Daudi, were labeled with Cell Tracker Orange (CTO) prior to the addition of effector cells. Following co-incubation, 7 amino-actinomycin D (7-AAD) was added to measure death of target cells. The phenotype of effectors, viability of targets, the formation of tumor-effector cell conjugates and absolute numbers of all cells were measured based on light scatter (FSC/SSC), double discrimination of the fluorescence peak integral and height, and fluorescence intensity. Kinetic studies (0.5 and 1 to 4 h) at different effector to target (E:T) cell ratios (50, 25, 12, and 6) confirmed that the 3 h incubation was optimal. The FCC assay is more sensitive than the CRA, has a coefficient of variation (CV) 8-13% and reliably measures NK cell-or lymphokine-activated killer (LAK) cell-mediated killing of target cells in normal controls and subjects with cancer. The FCC assay can be used to study a range of phenotypic attributes, in addition to lytic activity of various subsets of effector cells, without radioactive tracers and thus, it is relatively inexpensive. The FCC assay has a potential for providing information about molecular interactions underlying target cell lysis and thus becoming a major tool for studies of disease pathogenesis as well as development of novel immune therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17617419      PMCID: PMC2040258          DOI: 10.1016/j.jim.2007.05.013

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  33 in total

Review 1.  NKT cells - conductors of tumor immunity?

Authors:  Mark J Smyth; Nadine Y Crowe; Yoshihiro Hayakawa; Kazuyoshi Takeda; Hideo Yagita; Dale I Godfrey
Journal:  Curr Opin Immunol       Date:  2002-04       Impact factor: 7.486

2.  Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates.

Authors:  Luzheng Liu; Ann Chahroudi; Guido Silvestri; Mary E Wernett; William J Kaiser; Jeffrey T Safrit; Akira Komoriya; John D Altman; Beverly Z Packard; Mark B Feinberg
Journal:  Nat Med       Date:  2002-02       Impact factor: 53.440

Review 3.  Natural killer cell receptor signaling.

Authors:  Lewis L Lanier
Journal:  Curr Opin Immunol       Date:  2003-06       Impact factor: 7.486

4.  Multiparametric analysis of apoptosis by flow and image cytometry.

Authors:  William G Telford; Akira Komoriya; Beverly Z Packard
Journal:  Methods Mol Biol       Date:  2004

5.  Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry.

Authors:  Stephen P Perfetto; Pratip K Chattopadhyay; Laurie Lamoreaux; Richard Nguyen; David Ambrozak; Richard A Koup; Mario Roederer
Journal:  J Immunol Methods       Date:  2006-05-19       Impact factor: 2.303

6.  Caspase activity is not sufficient to execute cell death.

Authors:  Dunja Lukovic; Akira Komoriya; Beverly Z Packard; David S Ucker
Journal:  Exp Cell Res       Date:  2003-10-01       Impact factor: 3.905

7.  A new four-color flow cytometric assay to detect apoptosis in lymphocyte subsets of cultured peripheral blood cells.

Authors:  H J Hasper; R M Weghorst; D J Richel; J H Meerwaldt; F M Olthuis; C E Schenkeveld
Journal:  Cytometry       Date:  2000-06-01

8.  Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.

Authors:  Loredana Ruggeri; Marusca Capanni; Elena Urbani; Katia Perruccio; Warren D Shlomchik; Antonella Tosti; Sabrina Posati; Daniela Rogaia; Francesco Frassoni; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

9.  Cell-mediated cytotoxicity evaluation using monoclonal antibody staining for target or effector cells with annexinV/propidium iodide colabeling by fluorosphere-adjusted counts on three-color flow cytometry.

Authors:  Oner Ozdemir; Yaddanapudi Ravindranath; Süreyya Savaşan
Journal:  Cytometry A       Date:  2003-11       Impact factor: 4.355

Review 10.  Measuring T cell-mediated cytotoxicity using fluorogenic caspase substrates.

Authors:  A Chahroudi; G Silvestri; M B Feinberg
Journal:  Methods       Date:  2003-10       Impact factor: 3.608

View more
  54 in total

1.  Acute lymphoblastic leukemia cells that survive combination chemotherapy in vivo remain sensitive to allogeneic immune effects.

Authors:  Johan Jansson; Yu-Chiao Hsu; Igor I Kuzin; Andrew Campbell; Craig A Mullen
Journal:  Leuk Res       Date:  2010-11-12       Impact factor: 3.156

2.  IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients.

Authors:  B Schilling; E S Halstead; P Schuler; M Harasymczuk; J E Egan; T L Whiteside
Journal:  Cancer Immunol Immunother       Date:  2012-01-20       Impact factor: 6.968

3.  CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis.

Authors:  Hyun-Bae Jie; Patrick J Schuler; Steve C Lee; Raghvendra M Srivastava; Athanassios Argiris; Soldano Ferrone; Theresa L Whiteside; Robert L Ferris
Journal:  Cancer Res       Date:  2015-04-01       Impact factor: 12.701

4.  Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer.

Authors:  Sonja Ludwig; Theofanis Floros; Marie-Nicole Theodoraki; Chang-Sook Hong; Edwin K Jackson; Stephan Lang; Theresa L Whiteside
Journal:  Clin Cancer Res       Date:  2017-04-11       Impact factor: 12.531

Review 5.  Multispectral imaging of hematopoietic cells: where flow meets morphology.

Authors:  Kathleen E McGrath; Timothy P Bushnell; James Palis
Journal:  J Immunol Methods       Date:  2008-05-15       Impact factor: 2.303

6.  Methods to evaluate cytotoxicity and immunosuppression of combustible tobacco product preparations.

Authors:  Subhashini Arimilli; Brad E Damratoski; Prasad G L
Journal:  J Vis Exp       Date:  2015-01-10       Impact factor: 1.355

7.  EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors.

Authors:  Christopher H Evans; Fangjun Liu; Ryan M Porter; Regina P O'Sullivan; Taha Merghoub; Elaine P Lunsford; Kyle Robichaud; Frans Van Valen; Stephen L Lessnick; Mark C Gebhardt; James W Wells
Journal:  Clin Cancer Res       Date:  2012-08-09       Impact factor: 12.531

8.  Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15.

Authors:  Lazar Vujanovic; David E Szymkowski; Sean Alber; Simon C Watkins; Nikola L Vujanovic; Lisa H Butterfield
Journal:  Blood       Date:  2010-04-29       Impact factor: 22.113

9.  Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.

Authors:  Holbrook E Kohrt; Ariane Thielens; Aurelien Marabelle; Idit Sagiv-Barfi; Caroline Sola; Fabien Chanuc; Nicolas Fuseri; Cécile Bonnafous; Debra Czerwinski; Amanda Rajapaksa; Erin Waller; Sophie Ugolini; Eric Vivier; François Romagné; Ronald Levy; Mathieu Bléry; Pascale André
Journal:  Blood       Date:  2013-12-10       Impact factor: 22.113

10.  Both conventional and interferon killer dendritic cells have antigen-presenting capacity during influenza virus infection.

Authors:  Corine H GeurtsvanKessel; Ingrid M Bergen; Femke Muskens; Louis Boon; Henk C Hoogsteden; Albert D M E Osterhaus; Guus F Rimmelzwaan; Bart N Lambrecht
Journal:  PLoS One       Date:  2009-09-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.